Literature DB >> 27555151

Prophylactic use of tranexamic acid combined with thrombelastogram guided coagulation management may reduce blood loss and allogeneic transfusion in pediatric hemispherectomy: case series.

Wei Xiao1, Wenya Fu2, Tianlong Wang3, Lei Zhao4.   

Abstract

Hemispherectomy is an established surgical procedure to treat medically refractory epilepsy caused by diffuse hemispheric diseases. The most common complication of hemispherectomy is intraoperative bleeding. Perioperative allogeneic blood transfusion increases mortality and morbidity in pediatric patients. Etiologies of massive blood loss during hemispherectomy include intraoperative diffuse vascular damage, antileptic drugs induced coagulation dysfunction, hyperfibrinolysis and dilutional coagulopathy. Great efforts should be made to minimize the need of blood transfusion. We present a series of three cases undergoing pediatric hemispherectomy, where a new algorithm was employed to manage coagulation. This new algorithm was mainly based on timely thrombelastogram analyses guided clotting factors supplement and continuous administration of tranexamic acid. In our cases, the amount of blood loss and subsequent allogeneic blood transfusion seemed to be less than literature reported.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Children; Coagulation management; Hemispherectomy; Thrombelastrogram; Tranexamic acid

Mesh:

Substances:

Year:  2016        PMID: 27555151     DOI: 10.1016/j.jclinane.2016.02.040

Source DB:  PubMed          Journal:  J Clin Anesth        ISSN: 0952-8180            Impact factor:   9.452


  1 in total

1.  Prophylactic administration of tranexamic acid combined with thromboelastography-guided hemostatic algorithm reduces allogeneic transfusion requirements during pediatric resective epilepsy surgery: A randomized controlled trial.

Authors:  Ting Zhang; Hua Feng; Wei Xiao; Jingsheng Li; Qinghai Liu; Xuexin Feng; Dezhou Qi; Xiaotong Fan; Yongzhi Shan; Tao Yu; Guoguang Zhao; Tianlong Wang
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.